May 13,2022

Laboratory Protocol and Pilot Results for Dynamic Interference Testing of Continuous Glucose Monitoring Sensors

Testing the potential influence of interfering substances on the measurement performance of needle sensors for continuous glucose monitoring (CGM) is a challenging task. For proper function, the sensors need an almost stable fluidic environment.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 13,2022

Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate milestones.

View Analyst & Ambassador Comments
Go to original news
May 09,2022

Rimidi and ARKRAY Partner to Bring Glucose Data from the GLUCOCARD® Shine Connex Blood Glucose Monitoring System to the EHR

As a result of the collaboration, ARKRAY’s GLUCOCARD® Shine Connex Blood Glucose Monitoring System is now integrated with the Rimidi Platform, making blood glucose data more actionable for providers and patients alike.

COLLABORATION PARTNERSHIP

#connected device

#bgm

View Analyst & Ambassador Comments
Go to original news
May 16,2022

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Terumo Corporation (TSE: 4543) today announces that the indication for the Dexcom G6 CGM System has changed in Japan as of May 10, 2022. With this new indication, the Dexcom G6 CGM System will be the only real-time continuous glucose monitoring system (RT-CGM) in Japan that can be used principally for day-to-day management of blood glucose levels without the adjunctive use of a blood glucose meter. Terumo holds the exclusive distribution agreement rights to distribute this product in Japan, and it has been available for Japanese patients with diabetes since 2021.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 16,2022

Labcorp Launches First-of-its-kind At-home Collection Device for Diabetes Risk Testing

Labcorp (NYSE: LH), a leading global life sciences company, is making screening for diabetes easier with the launch of an at-home collection kit through Labcorp OnDemand™ that measures hemoglobin A1c (HbA1c) from a small blood sample.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
May 16,2022

How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7

A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. Dexcom Chief Technology Officer Jake Leach recently told that while the excitement around G7 remains, the San Diego-based company has more to offer.

View Analyst & Ambassador Comments
Go to original news
May 16,2022

Liva Healthcare appoints Sarah Beeby to lead growth in the UK market

Liva Healthcare (Liva), a European market leader in scalable digital health coaching, has appointed Sarah Beeby as Managing Director, UK.

View Analyst & Ambassador Comments
Go to original news
May 16,2022

Senseonics to Participate in the H.C. Wainwright Global Investment Conference

Senseonics announced plans to participate in the upcoming hybrid H.C. Wainwright Global Investment Conference and hold one on-one-meetings Tuesday, May 24, 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 01,2022

Commencement of flash glucose monitoring is associated with a decreased rate of depressive disorders among persons with diabetes (FLARE-NL7)

This study aims to assess the effects of commencement of FreeStyle Libre flash glucose monitoring (FSL-FGM) on the mental health status of persons with diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 01,2022

Beta Bionics looks to reduce ‘cognitive burden’ for those with diabetes with bionic pancreas

Beta Bionics’ iLet bionic pancreas offers insulin therapy without some of the hurdles associated with treating diabetes. Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more. With Beta Bionics's iLet bionic pancreas, the user inputs just one number: their body weight.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES